| abstract |
The present disclosure is directed to Buprenorphine Analog compounds of the Formula (I). Compounds of the disclosure are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors. In one embodiment the compound is (4R,4aS,6S,7R,7aR,12bS)-6-((benzylsulfonyl)methyl)-3-(cyclopropylmethyl)-7,9-dimethoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline. |